Altogether, our data revealed that CHAF1B is negatively correlated with HCC cell response to sorafenib, and significant antitumor activity could be achieved through the combination of CHAF1B knockdown and sorafenib treatment in HCC. Here, CHAF1B is linked to hepatocellular carcinoma.